ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FMTX Forma Therapeutics Holdings Inc

20.01
0.00 (0.00%)
Pre Market
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Forma Therapeutics Holdings Inc NASDAQ:FMTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.01 19.98 19.40 0 00:00:00

Forma Therapeutics to Participate in Upcoming Investor Conferences

04/11/2020 12:05pm

Business Wire


Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more Forma Therapeutics Charts.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in three upcoming investor conferences.

  • The Credit Suisse 29th Annual Healthcare Conference taking place November 9-12. Forma will present via webcast on Wednesday, November 11 at 2:45 p.m. Eastern Standard Time (EST).
  • The Jefferies 2020 Virtual London Healthcare Conference taking place November 17-19. Forma will present via webcast on Wednesday, November 18 at 7:55 p.m. Greenwich Mean Time (GMT).
  • The Virtual SVB Leerink Oncology 1X1 Day taking place November 19. Forma will participate virtually in one-on-one meetings during this event on Thursday, November 19.

A live webcast of the presentations at the Credit Suisse and Jefferies conferences will be available in the “News & Investors” section of Forma’s website at www.formatherapeutics.com.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

Media Contact: Kari Watson, +1 781-235-3060 MacDougall kwatson@macbiocom.com

Investor Contacts: Mario Corso, +1 781-366-5726 Forma Therapeutics, Inc. mcorso@formatherapeutics.com

Stephanie Ascher, +1 212-362-1200 Stern Investor Relations stephanie.ascher@sternir.com

1 Year Forma Therapeutics Chart

1 Year Forma Therapeutics Chart

1 Month Forma Therapeutics Chart

1 Month Forma Therapeutics Chart

Your Recent History

Delayed Upgrade Clock